Indications
Minjuvi is indicated in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).
Composition
- Active substance
- tafasitamab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Minjuvi
- Active substance
- tafasitamab
- ATC code
- L01FX12
- Therapeutic area
- Lymphoma, Large B-Cell, Diffuse
- Marketing authorisation holder
- Incyte Biosciences Distribution B.V.